AChE inhibitor therapy would best start at the earliest appearance of subtle cognitive impairment [15,16,81], a point at which signs of neurodegeneration are the earliest and most common biomarkers of AD and that often precede and predict the accumulation of amyloid [16,17,18]. Here, ACHE is linked to Alzheimer disease.